Offer - Urjas Oil for just ₹ 1 X
Gemciglan, a prescription drug, is manufactured in various forms such as Injection. It is typically used for the treatment of Pancreatic Cancer, Non-Small Cell Lung Cancer. The alternative uses of Gemciglan have also been explained below.
The optimal dosage of Gemciglan is largely dependent on the individual's body weight, medical history, gender and age. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
Some other side effects of Gemciglan have been listed ahead. Such side effects of Gemciglan normally do not last long and go away once the treatment is completed. However, if these continue for a longer time, consult your doctor right away.
In addition, Gemciglan's effect is Unknown during pregnancy and Severe for lactating mothers. Further, the section on Gemciglan related warnings talks about Gemciglan's effects on the liver, heart and kidney.
Gemciglan is contraindicated in people with pre-existing medical conditions like Heart Disease, Infections as it can result in adverse effects. The section on Gemciglan contraindications lists all such conditions.
Additionally, Gemciglan may also adversely react with other medicines. Refer to the list below for further details.
In addition to these precautions, you may also note that Gemciglan is safe while driving, and is is addictive in nature.
Gemciglan is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult(Female) |
|
Adult |
|
Geriatric |
|
Is the use of Gemciglan safe for pregnant women?
No research has been done to ascertain the safety of Gemciglan in pregnant women. If you are pregnant, it is best to ask a doctor to know if you can take it.
Is the use of Gemciglan safe during breastfeeding?
Taking Gemciglan may lead to serious side effects if you are breastfeeding. Gemciglan should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Gemciglan on the Kidneys?
Gemciglan has very mild side effects on the kidneys.
What is the effect of Gemciglan on the Liver?
The liver can be affected by Gemciglan. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart Gemciglan only after medical advice.
What is the effect of Gemciglan on the Heart?
Gemciglan may have mild side effects on the heart. Most people will never see any effect on the heart.
Gemciglan should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Gemciglan unless your doctor advises you to do so -
Is this Gemciglan habit forming or addictive?
Forming a habit of Gemciglan has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
Yes, it is safe to do these activities or work after taking Gemciglan as it does not make you drowsy.
Is it safe?
Yes, but consume Gemciglan only on doctor's advice.
Is it able to treat mental disorders?
No, Gemciglan is not used to treat mental disorders.
Interaction between Food and Gemciglan
There isn't any research available on the side effects of taking Gemciglan with food.
Interaction between Alcohol and Gemciglan
Due to lack of research, there is no information about the side effects of taking Gemciglan with alcohol.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Gemzar® (Gemcitabine HCl)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 612-614